Tocilizumab in Post Hematopoietic Stem Cell Transplant COVID-۱۹: A Pediatric Case Report

Hematopoietic stem cell transplantation (HSCT) severely undermines the recipients' immune status and makes them prone to complications following viral infection. Here, we report a ۳-year-old boy with mucopolysaccharidosis type VI who acquired SARS-CoV-۲ infection after HSCT. The boy was diagnosed with SARS-CoV-۲ during the post-transplant period (۱۹ days after HSCT) when dealing with acute graft versus host disease (GVHD). He was successfully treated with remdesivir and tocilizumab and recovered. Well-timed treatment with tocilizumab might reduce the risk of invasive mechanical ventilation and death in patients with severe COVID-۱۹ pneumonia in the early post HSCT period.

Keywords:

Post Hematopoietic Stem Cell Transplantation , COVID-۱۹ , Mucopolysaccharidosis